However, Boschman et al. (Boschmann et al., 2009) and Matikainen et al. (Matikainen et al., 2006) have reported the effects of vildagliptin therapy on post-prandial lipid mobilization, oxidation and lipoprotein metabolism in patients with T2DM, where DPP-4 inhibitor course ameliorated triglyceride and apolipoprotein B-48 particle digestion after a fat-rich meal. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.